Brief: Pfizer Says Padcev Plus Keytruda Improves Survival for Certain Bladder Cancer Patients Pre/Post-Surgery
12/08/2025 10:30
Aug 12 (Reuters) - Pfizer: PFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR CERTAIN PATIENTS WITH BLADDER CANCER WHEN GIVEN BEFORE & AFTER SURGERY PFIZER: ADDITIONAL SECONDARY ENDPOINT OF PATHOLOGIC COMPLETE RESPONSE RATE MET PFIZER: PHASE 3 EV-303 CLINICAL TRIAL RESULTS TO BE DISCUSSED WITH GLOBAL HEALTH AUTHORITIES FOR POTENTIAL GLOBAL REGULATORY FILINGS PFIZER: SAFETY PROFILES FOR PADCEV PLUS KEYTRUDA & KEYTRUDA MONOTHERAPY CONSISTENT WITH KNOWN PROFILES OF EACH TREATMENT REGIMEN Source text: [ID:] Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn